Interpace Diagnostics

Interpace Diagnostics is a healthcare commercialization company providing go-to-market strategy and execution to established and emerging pharmaceutical, biotechnology, diagnostics and healthcare companies in the United States. The company operates a molecular diagnostics company that helps physicians better manage patients at risk for certain types of gastrointestinal cancers through its proprietary PathFinderTG platform. Its PathfinderTG platform uses advanced clinical algorithms to accurately stratify patients according to risk of cancer by assessing panels of DNA abnormalities in patients who have lesions (i.e., cysts or solid masses) with potential for cancer.
Company Growth (employees)
Type
Public
HQ
Parsippany Troy Hills, US
Founded
1987
Size (employees)
61 (est)-6%
Interpace Diagnostics was founded in 1987 and is headquartered in Parsippany-Troy Hills, US

Interpace Diagnostics Office Locations

Interpace Diagnostics has an office in Parsippany-Troy Hills
Parsippany-Troy Hills, US (HQ)
300 Interpace Pkwy

Interpace Diagnostics Financials and Metrics

Interpace Diagnostics Financials

Interpace Diagnostics's revenue was reported to be $13.1 m in FY, 2016
USD

Revenue (Q2, 2017)

3.9 m

Gross profit (Q2, 2017)

2 m

Gross profit margin (Q2, 2017), %

51%

Net income (Q2, 2017)

(6.3 m)

EBIT (Q2, 2017)

(3.6 m)

Market capitalization (31-Oct-2017)

27 m

Closing share price (31-Oct-2017)

1.2

Cash (30-Jun-2017)

14.3 m
Interpace Diagnostics's current market capitalization is $27 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

150.8 m119.9 m9.4 m13.1 m

Revenue growth, %

(20%)(92%)39%

Cost of goods sold

126.4 m101.4 m6.9 m6.6 m

Gross profit

24.4 m18.5 m2.5 m6.4 m
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

32.8 m31.6 m29.2 m38.3 m36.3 m36.6 m3 m3.6 m3.3 m3.5 m3.9 m

Cost of goods sold

27.7 m26.8 m25.5 m30.7 m30.2 m29.4 m1.2 m1.8 m1.8 m1.8 m1.9 m

Gross profit

5.1 m4.8 m3.7 m7.6 m6.1 m7.2 m1.9 m1.8 m1.5 m1.7 m2 m

Gross profit Margin, %

16%15%13%20%17%20%61%49%44%49%51%
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

45.6 m23.1 m8.3 m602 k

Accounts Receivable

2.4 m8.5 m2.8 m2.2 m

Current Assets

62.7 m44.9 m19.2 m4.2 m

PP&E

2.8 m3.2 m1.5 m929 k
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

37.9 m35.6 m27 m17 m14.4 m9 m4.3 m3 m1.7 m7.1 m14.3 m

Accounts Receivable

8.5 m3.8 m3.4 m13.4 m11.9 m12.3 m2.8 m3 m2.8 m2.3 m2.7 m

Current Assets

59 m53.2 m42.2 m43.1 m39.3 m32.1 m11.7 m9.6 m6.7 m10.7 m18.3 m

PP&E

2.8 m2.8 m2.9 m3.3 m3.1 m2.8 m1.3 m1.2 m1.1 m770 k644 k
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(4.6 m)(16.1 m)(11.4 m)(8.3 m)

Depreciation and Amortization

4.5 m

Accounts Receivable

4.8 m

Accounts Payable

143 k
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(1.6 m)(2.7 m)(4.3 m)(3.9 m)(7 m)(4.9 m)(4.8 m)(2.3 m)(7.5 m)2.4 m(3.9 m)

Depreciation and Amortization

972 k1.9 m

Accounts Receivable

3.8 m3.4 m13.4 m11.9 m12.3 m2.8 m3 m2.8 m(90 k)

Accounts Payable

2.1 m2.9 m3 m4.4 m4.5 m1.2 m1.3 m1.4 m295 k
Y, 2017

Financial Leverage

1.5 x
Show all financial metrics

Interpace Diagnostics Operating Metrics

Interpace Diagnostics's Patent Applications was reported to be 16 in FY, 2016
FY, 2016

Facilities

2

Patents (foreign)

3

Products

3

Patents (US)

1
Show all operating metrics

Interpace Diagnostics Market Value History

Interpace Diagnostics's Web-traffic and Trends

Interpace Diagnostics Online and Social Media Presence

Interpace Diagnostics Company Life and Culture

You may also be interested in